Home ETF List About

Portfolio Holdings Detail for ISIN IE0003WV2ME7
Stock Name / FundiShares S&P 500 Equal Weight UCITS ETF GBP Hedged (Acc)
IssuerBlackrock
Entity holding fund iShares III Public Limited Company
Entity Type
Entity LEI 549300PZLRJB7M8H1057
ETF TickerISPE(GBP) LSE
ETF TickerISPE.L(GBP) LSE

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares S&P 500 Equal Weight UCITS ETF GBP Hedged (Acc) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-09-18 (Thursday)16,826REGN holding increased by 20USD 10,073,894REGN holding increased by 233981USD 10,073,89420USD 233,981 USD 598.71 USD 585.5
2025-09-17 (Wednesday)16,806USD 9,839,913REGN holding increased by 175455USD 9,839,9130USD 175,455 USD 585.5 USD 575.06
2025-09-16 (Tuesday)16,806USD 9,664,458REGN holding increased by 41510USD 9,664,4580USD 41,510 USD 575.06 USD 572.59
2025-09-15 (Monday)16,806USD 9,622,948REGN holding increased by 211588USD 9,622,9480USD 211,588 USD 572.59 USD 560
2025-09-12 (Friday)16,806USD 9,411,360USD 9,411,360
2025-09-10 (Wednesday)16,806USD 9,341,279USD 9,341,279
2025-09-09 (Tuesday)16,816USD 9,358,608USD 9,358,608
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE0003WV2ME7

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-18BUY20 598.710* 653.66
2025-08-18BUY18 573.910* 655.26
2025-08-12SELL-10 556.555* 657.16 Profit of 6,572 on sale
2025-07-31SELL-411 545.460* 657.75 Profit of 270,337 on sale
2025-07-29BUY11 558.145* 658.85
2025-07-23SELL-30 572.390* 660.39 Profit of 19,812 on sale
2025-07-22SELL-60 560.930* 660.94 Profit of 39,657 on sale
2025-07-21SELL-20 545.530* 661.58 Profit of 13,232 on sale
2025-07-15SELL-20 547.960* 662.86 Profit of 13,257 on sale
2025-07-14SELL-50 570.590* 663.38 Profit of 33,169 on sale
2025-07-11SELL-30 567.740* 663.93 Profit of 19,918 on sale
2025-07-10SELL-120 559.760* 664.52 Profit of 79,743 on sale
2025-07-09SELL-40 552.580* 665.17 Profit of 26,607 on sale
2025-07-08SELL-130 547.750* 665.84 Profit of 86,560 on sale
2025-07-03SELL-170 547.360* 667.99 Profit of 113,558 on sale
2025-07-02SELL-31 547.740* 668.70 Profit of 20,730 on sale
2025-06-30BUY446 525.000* 669.56
2025-06-27SELL-490 521.000* 670.45 Profit of 328,518 on sale
2025-06-25BUY10 520.290* 672.26
2025-06-24SELL-370 522.270* 673.18 Profit of 249,075 on sale
2025-06-23SELL-10 511.920* 674.17 Profit of 6,742 on sale
2025-06-20BUY5,426 509.720* 675.18
2025-06-18SELL-42 513.580* 677.20 Profit of 28,442 on sale
2025-06-17SELL-77 508.860* 678.26 Profit of 52,226 on sale
2025-06-11SELL-21 518.600* 680.27 Profit of 14,286 on sale
2025-06-10SELL-49 523.530* 681.28 Profit of 33,383 on sale
2025-06-06SELL-14 493.220* 683.56 Profit of 9,570 on sale
2025-06-05SELL-119 483.070* 684.87 Profit of 81,500 on sale
2025-06-02SELL-567 490.810* 688.81 Profit of 390,556 on sale
2025-05-30SELL-126 490.280* 690.14 Profit of 86,958 on sale
2025-05-29SELL-14 605.390* 690.72 Profit of 9,670 on sale
2025-05-27SELL-14 603.260* 691.99 Profit of 9,688 on sale
2025-05-23SELL-21 588.340* 693.43 Profit of 14,562 on sale
2025-05-16SELL-105 594.320* 696.74 Profit of 73,158 on sale
2025-05-15SELL-21 584.990* 697.55 Profit of 14,649 on sale
2025-05-13SELL-7 574.160* 699.39 Profit of 4,896 on sale
2025-05-12SELL-49 575.630* 700.30 Profit of 34,315 on sale
2025-05-09SELL-42 527.780* 701.59 Profit of 29,467 on sale
2025-05-08SELL-203 547.670* 702.75 Profit of 142,658 on sale
2025-05-07SELL-14 560.930* 703.82 Profit of 9,854 on sale
2025-05-06BUY8 558.520* 704.93
2025-05-01BUY266 590.000* 707.40
2025-04-30BUY147 598.760* 708.25
2025-04-29SELL-28 568.910* 709.36 Profit of 19,862 on sale
2025-04-28SELL-35 610.860* 710.15 Profit of 24,855 on sale
2025-04-25BUY14 602.640* 711.01
2025-04-24SELL-7 599.760* 711.92 Profit of 4,983 on sale
2025-04-22SELL-938 585.490* 713.99 Profit of 669,722 on sale
2025-04-17SELL-427 563.160* 717.84 Profit of 306,517 on sale
2025-04-16BUY14 549.280* 719.28
2025-04-15BUY14 557.910* 720.67
2025-04-10SELL-441 546.390* 725.01 Profit of 319,729 on sale
2025-04-09BUY35 576.720* 726.33
2025-04-08BUY7 556.810* 727.86
2025-04-07BUY126 572.780* 729.27
2025-04-04BUY77 573.450* 730.70
2025-04-02BUY49 625.600* 731.67
2025-04-01BUY553 617.000* 732.74
2025-03-31BUY21 634.230* 733.67
2025-03-25BUY7 634.140* 737.47
2025-03-21BUY578 658.480* 739.02
2025-03-20BUY14 662.620* 739.80
2025-03-18BUY35 664.960* 741.26
2025-03-17BUY7 678.420* 741.92
2025-03-13SELL-420 680.610* 743.37 Profit of 312,215 on sale
2025-03-12BUY84 689.500* 743.95
2025-03-11BUY84 718.160* 744.23
2025-03-07BUY28 707.510* 744.63
2025-03-06BUY98 698.440* 745.15
2025-03-05BUY532 687.150* 745.81
2025-03-04BUY28 675.490* 746.62
2025-03-03BUY35 684.870* 747.33
2025-02-28BUY70 698.740* 747.91
2025-02-27BUY63 702.780* 748.44
2025-02-26SELL-35 706.940* 748.94 Profit of 26,213 on sale
2025-02-25SELL-7 723.470* 749.25 Profit of 5,245 on sale
2025-02-24BUY7 713.250* 749.70
2025-02-20SELL-91 696.020* 751.00 Profit of 68,341 on sale
2025-02-19BUY28 685.660* 751.84
2025-02-18BUY28 680.000* 752.77
2025-02-13BUY798 674.270* 755.97
2025-02-12BUY238 663.860* 757.24
2025-02-11BUY196 665.460* 758.51
2025-02-07BUY21 710.000* 760.18
2025-02-06BUY280 722.070* 760.73
2025-02-05BUY140 716.720* 761.38
2025-02-04BUY105 697.050* 762.34
2025-02-03SELL-609 666.850* 763.78 Profit of 465,144 on sale
2025-01-31BUY56 672.980* 765.18
2025-01-30BUY7 683.080* 766.46
2025-01-29BUY119 687.270* 767.72
2025-01-28BUY42 686.330* 769.03
2025-01-27BUY42 684.710* 770.41
2025-01-24BUY42 675.790* 771.99
2025-01-23BUY119 694.640* 773.30
2025-01-22BUY70 680.030* 774.91
2025-01-21BUY413 687.800* 776.44
2025-01-17BUY84 681.580* 779.89
2025-01-15BUY42 703.430* 782.97
2025-01-13BUY119 716.900* 786.07
2025-01-10BUY91 696.880* 787.85
2024-12-31BUY21 712.330* 793.43
2024-12-30BUY28 702.590* 795.45
2024-12-27BUY133 712.400* 797.34
2024-12-23BUY42 715.130* 803.33
2024-12-20BUY4,328 701.850* 805.87
2024-12-19BUY48 708.250* 808.37
2024-12-17BUY36 740.010* 812.75
2024-12-16BUY12 724.870* 815.19
2024-12-13BUY20 731.300* 817.59
2024-12-11BUY12 773.000* 818.90
2024-12-10BUY8 778.500* 820.13
2024-12-09BUY8 788.000* 821.13
2024-12-05SELL-24 767.900* 824.34 Profit of 19,784 on sale
2024-12-04BUY4 754.260* 826.76
2024-12-02BUY16 762.340* 832.00
2024-11-29BUY72 750.220* 835.15
2024-11-27BUY16 754.870* 841.84
2024-11-26BUY40 753.030* 845.70
2024-11-25BUY496 749.510* 850.07
2024-11-22BUY12 738.000* 855.41
2024-11-21BUY12 744.500* 860.96
2024-11-20BUY52 743.350* 867.15
2024-11-19SELL-52 744.600* 873.95 Profit of 45,446 on sale
2024-11-18BUY240 762.000* 880.54
2024-11-12BUY48 821.000* 884.26
2024-11-11BUY12 825.680* 888.17
2024-11-08BUY48 828.420* 892.43
2024-11-07BUY80 824.480* 897.66
2024-11-06BUY36 816.650* 904.41
2024-11-05BUY8 829.430* 911.23
2024-11-04BUY40 828.840* 919.47
2024-11-01BUY20 843.600* 927.90
2024-10-31SELL-184 838.200* 939.11 Profit of 172,796 on sale
2024-10-30BUY12 922.790* 941.44
2024-10-29BUY76 927.330* 943.79
2024-10-25BUY16 933.020* 950.28
2024-10-24BUY12 928.900* 957.41
2024-10-22BUY24 962.340* 968.50
2024-10-21BUY20 968.500* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.